Peer Review History
Original SubmissionSeptember 1, 2020 |
---|
PONE-D-20-27466 A deterministic linear infection model to inform Risk-Cost-Benefit Analysis of activities during the SARS-CoV-2 pandemic PLOS ONE Dear Dr. McCarthy, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. All reviewers expressed concerns that warrant a major revision. Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact. ============================== Please submit your revised manuscript by Nov 08 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Igor Linkov Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Competing Interests section: "JEM, BAD and MTM received funding from Delaware North, a company that may be affected by the research reported in the paper.". We note that one or more of the authors are employed by a commercial company: 'Omnium LLC'. 1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. * Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. We note you have included tables to which you do not refer in the text of your manuscript. Please ensure that you refer to Tables 1 and 4 in your text; if accepted, production will need this reference to link the reader to the Table. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: No Reviewer #3: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: McCarthy et al. have formulated a “deterministic linear” modeling framework to inform risk-cost-benefit analysis of activities during the SARS-CoV-2 pandemic. The model outputs infection probabilities that are additive over defined sub-activities and infection pathways. Namely, the model assumes independence of the individual probabilities and that activities cannot last longer than one day. Then, the model is applied to estimate the risk associated with taking an airplane ride, under varying parameter choices. Furthermore, the authors argue that the linearity assumption makes the model easier to interpret, with minimal sacrifice in reliability. This is a very timely topic and I would like to applaud the authors for tackling this topic using a more abstract, mathematical framework. The results suggest that the model has a high potential utility in estimating relative risks associated with various activities. I would recommend this paper for acceptance, but believe a couple aspects of the manuscript could be thoroughly revised. First, the paper needs further clarity in terms of definitions (i.e., “deterministic” model), assumptions, and presentation of the mathematics. Second, the model application to the airplane ride example should consider a wider range of parameters and augmented interpretation of estimated risk values. These revisions to the paper will enhance the demonstration of the model’s potential ability for application in risk estimation and decision making. More detailed comments are provided in the attached document. Reviewer #2: During the COVID-19 pandemic, difficult decisions are being made which trade off the risk of infection with the reward of normal activity. This paper addresses the challenge of making such decisions, and provides a practical simplified type of analysis. The question is whether the simplified analysis is fit for practical purpose. The simplified example selected for detailed study is air travel. As a former safety consultant for a major international airline, I know that all major airlines will have undertaken their own far more elaborate safety studies to make flying as COVID-19 secure as possible. These studies will include tests of aerosol dispersion within planes, and the practical effectiveness of sanitization measures. Almost 200 passengers were on board a flight from the Greek island of Zante to Cardiff, Wales, on August 25. As many as seven people from three parties were infectious on the plane. Sixteen have since tested positive for the coronavirus. According to passengers, the flight attendants did not enforce the COVID-19 rules sufficiently. The largest concern over flying is being on a plane where a group of younger asymptomatic passengers may flout the rules about keeping their face coverings on, instead leaving them round their chins. Flouting of rules is itself a contagious mode of human behavior. Once a number of passengers remove their face coverings, others will follow. Passengers may also wander around the cabin to talk with friends without face coverings. Disregard of COVID-19 rules on board a plane is not taken into account in the authors’ air travel example. For any mass gathering of people, e.g. stadiums, disregard of COVID-19 rules is a serious worry. Over the summer, outdoor sports stadiums could have allowed 10% of the usual number of spectators, who could be easily socially distanced. The concern has been over the deliberate violation of social distancing measures. The authors’ paper should be revised to include a substantial improvement to their air travel example. Recognition of noncompliant human behaviour is essential to be realistic. Reviewer #3: Review of PONE-D-20-27466 “A deterministic linear infection model…” by McCarthy et al. The paper seems to argue that there needs to be a way to compute relative risks that is simpler for decision makers to break down and interpret. I agree that this is a worthy avenue of research, as communicating the impact of risk reduction in the aid of proper policy design is crucial to seeing us safely through this pandemic. However, I believe this manuscript should not be published for the following reasons. • The paper’s conclusions reflect the input assumptions in a way that makes it appear to be an elaboration of the obvious. It would be more interesting and helpful if the paper’s model were used to compare strategies, demonstrate some surprising conclusion, or compute (believable) quantitative results. • Simply adding together probabilities, rather than computing the “probabilistic sum”, is called the rare event approximation in risk analysis. This method is used without relevant reference, and in a circumstance where it is arguably inappropriate as the estimated events are not rare. The correct calculation with the probabilistic sum is not much more complicated, and need not necessarily be a barrier in communicating with policy analysts. • Statements in the discussion such as “Making masks mandatory, and enforcing this rule, is clearly the most cost-effective strategy” are not supported by any of the analysis in the manuscript. I would not dispute this claim, but it is not in any way supported by the example given, nor are most of the other claims in the final paragraph of the discussion where the example is brought up. • Assumption A6 is a requirement for the proof of A1, and therefore when A6 is being questioned, A1 is being questioned in the discussion. Considering A1 is a foundational assumption for the manuscript this is cause for concern. I agree that this assumption should be questioned, but the paper itself seems to be questioning whether it is valid. The authors begin to acknowledge this issue, but their discussion seems insufficient. • The independence assumption in A2 and A6 is also perhaps not justified in the example given. For example, the suggested means of boarding back to front without disrupting queuing order would place passengers mostly in close proximity to those they had queued with. Therefore the risk of infection whilst seated would be highly dependent on the risk of infection whilst queuing. • Assumption A4 notes that the risk of infection depends not only on the distance from the neighbour, but the direction they are facing etc. This assumption is not consistent with the example given, or its application is not apparent. The equation in 3.1 seems to treat all passengers within a queue equally, indicating that the direction they are facing is not a relevant factor. • Assumption A7 assumes that multiple individuals from the same household do not infect each other and that this assumption is important when applying the model. This assumption is not justified, nor is the implied importance of the assumption ever discussed. Also a point of the discussion notes the impact of households of three travelling together as an additional consideration when leaving middle seats vacant, despite this being perfectly possible whilst maintaining vacant middle seats. • The model allows for transmission through airborne particulates, touching contaminated surfaces and direct physical contact. Yet, in the example that is given the latter two are assumed to be of negligible impact. • Use of non-SI units. • References poorly formatted. • Non-standard use of pi before definition. • Equations are not numbered throughout. • Doesn’t meet the PLOS ONE formatting requirements. For example appendix 8 contains an important definition that would benefit from being in the main body of the text. • Additional case studies might improve the manuscript. For instance, what would the impact of different boarding policies be? The authors assume that the aircraft will be seated from back to front perfectly, but the impact of this happening imperfectly could be discussed. As could the impact of having an unordered boarding policy. • The analysis could be improved by having examples where a decision has to be made between two scenarios that are not clear cut. It is fairly trivial to assume that having fewer people on an aircraft would lower the risk of one becoming infected. If there was an example such as having a full school attendance with everyone wearing a mask and limited social distancing versus only having half attendance with full social distancing (>2m) then the model may appear to be more useful. • The cited literature seems depauperate at best. There seem to be no publications on the subject of disease transmission from grouping on aircraft. They could have cited the recent JAMA article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769383?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081820 ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Gordon Woo Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
PONE-D-20-27466R1 Modeling the relative risk of SARS-CoV-2 infection to inform Risk-Cost-Benefit Analyses of activities during the SARS-CoV-2 pandemic PLOS ONE Dear Dr. McCarthy, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. One reviewer is critical, please address his concerns to the extent possible Please submit your revised manuscript by Feb 06 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Igor Linkov Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: COVID-19 is a rapidly evolving crisis, and actual data are being gathered on infection sources to help make the type of decisions considered in this paper. Public policy is being driven by accumulating data on infections in restaurants, schools, places of worship etc.. In respect of sports stadiums, a prime concern has been on the travel to stadiums, some of which may involve public transport, and the mingling of fans in congested bars outside the stadiums. While the analysis that has been undertaken has some merit as an academic exercise, for practical decision-making, this is rather moot. Indeed, with the deployment of effective vaccines in the coming months, the analysis presented will cease to be of much practical relevance by the end of 2021. I tend to agree with the third reviewer about the publication of this paper. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 2 |
Modeling the relative risk of SARS-CoV-2 infection to inform Risk-Cost-Benefit Analyses of activities during the SARS-CoV-2 pandemic PONE-D-20-27466R2 Dear Dr. McCarthy, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Igor Linkov Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-20-27466R2 Modeling the relative risk of SARS-CoV-2 infection to inform Risk-Cost-Benefit Analyses of activities during the SARS-CoV-2 pandemic Dear Dr. McCarthy: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Igor Linkov Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .